Millennium Pharmaceuticals Limited

Takeda Pharmaceutical Company Limited

Dylan Bradley England

Steven P Langston

Hirotake Mizutani

He Xu

Matthew O Duffey

Zhigen Hu

Charles McIntyre

Koji Ono

Alexandra E Gould

Brian Scott Freeze

Stepan Vyskocil

Yongbo Hu

Gang Li

Courtney A Cullis

Paul D Greenspan

Jeffrey Ciavarri

Liting Ma

Charles Mcintyre

Kenneth M Gigstad

Mitsuhiro Ito

Masanori Okaniwa

Sean J Harrison

Emily Frances Calderwood

Shih-Chung Huang

Sharmila Adhikari

Scott Freeze

The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I):

Sting modulator compounds, and methods of making and using

The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof. 

Disclosed are chemical entities which are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein R, R, and Rhave the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer. 

ATG7 inhibitors and the uses thereof

Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, R, R', R, R, X, X, X, R, Z, and Zhave the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

Heteroaryl compounds useful as inhibitors of SUMO activating enzyme

Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, R, R, R, R, X, X, X, R, Z, and Zhave the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

Disclosed are compounds of formula (I); or a pharmaceutically acceptable salt thereof; wherein Y, R, R, R, R, X, R, R, R, R, m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders. 

Heteroaryl inhibitors of sumo activating enzyme

This invention provides compounds of formula (I): 

Substituted hydroxamic acids and uses thereof

Growing community of inventors

Milford, MA, United States of America

Dylan Bradley England